Protocol No
ALLIANCE-ALCHEMIST-A151216
Phase
N/A
Summary
The goal is to conduct one integrated program for screening the target patient (early stage) lung cancer population to identify: EGFR mutations and ALK rearrangements. Patients can then be enrolled on 1 of 2 specific adjuvant trials testing the benefit of adding Erlotinib (EGFR) or Crizotinib (ALK) therapy after standard adjuvant therapy prescribed by the patients' treating physicians.
Description
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov